CNPR Product Knowledge 3 — Questions and Answers
Question 1: Which phase of clinical trials specifically evaluates a new drug's safety and determines safe dosage ranges in a small group of healthy volunteers?
- Phase I (Correct answer)
- Phase II
- Phase III
- Phase IV
Correct answer: Phase I
Phase I trials are the first stage of human testing, focusing on safety, tolerability, pharmacokinetics, and dosage in a small group, usually 20–80 healthy volunteers.
Question 2: A pharmaceutical representative is asked by a physician about a use of the drug not covered in the approved labeling. The rep should:
- Provide the physician with any available data on the topic
- Decline to discuss unapproved uses and offer to submit a medical information request (Correct answer)
- Refer the physician to a competitor's product instead
- Share anecdotal patient case reports to address the question
Correct answer: Decline to discuss unapproved uses and offer to submit a medical information request
Reps must not promote off-label uses; the appropriate response is to acknowledge the question and direct the request to the medical affairs department for a proper medical information response.
Question 3: What is the difference between a drug's brand name and its generic name?
- The generic name is the trademarked name given by the manufacturer; the brand name is the chemical name
- The brand name is the manufacturer's proprietary trade name; the generic name is the nonproprietary scientific name (Correct answer)
- Brand and generic names are interchangeable terms with no meaningful difference
- The generic name refers only to over-the-counter medications
Correct answer: The brand name is the manufacturer's proprietary trade name; the generic name is the nonproprietary scientific name
The brand name is the proprietary name trademarked by the manufacturer, while the generic name is the official nonproprietary name established by the United States Adopted Names (USAN) Council.
Question 4: Which term describes the unintended effects of a drug that occur at therapeutic doses and are not related to the intended pharmacological action?
- Contraindications
- Side effects (adverse effects) (Correct answer)
- Drug tolerance
- Potentiation
Correct answer: Side effects (adverse effects)
Side effects or adverse effects are undesired responses occurring at normal therapeutic doses that are separate from the drug's intended mechanism of action.
Question 5: In pharmacology, what does 'half-life' (t½) of a drug mean?
- The time for a drug to be completely eliminated from the body
- The time required for the plasma concentration of a drug to reduce by 50% (Correct answer)
- The duration of a drug's therapeutic effect
- The time between drug administration and onset of action
Correct answer: The time required for the plasma concentration of a drug to reduce by 50%
Half-life is the time required for the concentration of a drug in the bloodstream to decrease by half, which determines dosing intervals.
Question 6: What is the meaning of 'NDA' in the context of pharmaceutical drug approval?
- Non-Disclosure Agreement between a rep and a physician
- New Drug Application, the formal submission to the FDA requesting approval to market a new drug (Correct answer)
- National Drug Association, the regulatory body overseeing drug safety
- Narcotic Drug Authorization, required for Schedule II prescriptions
Correct answer: New Drug Application, the formal submission to the FDA requesting approval to market a new drug
A New Drug Application (NDA) is the comprehensive document submitted to the FDA containing all preclinical and clinical data to demonstrate a drug's safety and efficacy for approval.
Question 7: Which type of drug interaction occurs when two drugs are combined and their combined effect is greater than the sum of their individual effects?
- Antagonism
- Synergism (potentiation) (Correct answer)
- Additive effect
- Tolerance
Correct answer: Synergism (potentiation)
Synergism or potentiation describes a drug interaction where the combined effect exceeds the simple addition of each drug's individual effect (greater than 1+1=2).
CNPR Product Knowledge 3
Which phase of clinical trials specifically evaluates a new drug's safety and determines safe dosage ranges in a small group of healthy volunteers?